MX2021006029A - Pamoato de ketamina y su uso. - Google Patents

Pamoato de ketamina y su uso.

Info

Publication number
MX2021006029A
MX2021006029A MX2021006029A MX2021006029A MX2021006029A MX 2021006029 A MX2021006029 A MX 2021006029A MX 2021006029 A MX2021006029 A MX 2021006029A MX 2021006029 A MX2021006029 A MX 2021006029A MX 2021006029 A MX2021006029 A MX 2021006029A
Authority
MX
Mexico
Prior art keywords
pamoate
ketamine
salts
ketamine pamoate
anesthetic
Prior art date
Application number
MX2021006029A
Other languages
English (en)
Inventor
Tong - Ho Lin
Yung - Shun Wen
Chia - Hsien Chen
Wei - Ju CHANG
Original Assignee
Alar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alar Pharmaceuticals Inc filed Critical Alar Pharmaceuticals Inc
Publication of MX2021006029A publication Critical patent/MX2021006029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan sales de pamoato de ketamina que tienen una estequiometría de 2:1 de ketamina a pamoato, incluyendo pamoato de R, S-ketamina, pamoato de S-ketamina, o pamoato de R-ketamina, y formas cristalinas o amorfas de las sales de pamoato, y que tienen excelente seguridad y propiedades para aplicaciones farmacéuticas. También se proporcionan composiciones farmacéuticas que incluyen las sales de pamoato de la ketamina y sus usos en el tratamiento de una enfermedad del SNC o como anestésico.
MX2021006029A 2019-01-11 2020-01-10 Pamoato de ketamina y su uso. MX2021006029A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791058P 2019-01-11 2019-01-11
US201962871763P 2019-07-09 2019-07-09
PCT/CN2020/071404 WO2020143762A1 (en) 2019-01-11 2020-01-10 Ketamine pamoate and use thereof

Publications (1)

Publication Number Publication Date
MX2021006029A true MX2021006029A (es) 2021-09-23

Family

ID=71521952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006029A MX2021006029A (es) 2019-01-11 2020-01-10 Pamoato de ketamina y su uso.

Country Status (24)

Country Link
US (1) US11981617B2 (es)
EP (1) EP3908570B1 (es)
JP (1) JP7451538B2 (es)
KR (1) KR20210116517A (es)
CN (1) CN113423686B (es)
AU (1) AU2020206826B2 (es)
BR (1) BR112021013340A2 (es)
CA (1) CA3118954A1 (es)
CL (1) CL2021001803A1 (es)
CO (1) CO2021006884A2 (es)
DK (1) DK3908570T3 (es)
ES (1) ES2974259T3 (es)
FI (1) FI3908570T3 (es)
HR (1) HRP20240255T1 (es)
LT (1) LT3908570T (es)
MX (1) MX2021006029A (es)
PE (1) PE20211550A1 (es)
PH (1) PH12021551157A1 (es)
PT (1) PT3908570T (es)
RS (1) RS65271B1 (es)
SG (1) SG11202104792SA (es)
SI (1) SI3908570T1 (es)
TW (1) TWI827783B (es)
WO (1) WO2020143762A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753557A4 (en) 2018-02-15 2021-12-01 National University Corporation Chiba University PREVENTIVE OR THERAPEUTIC AGENT AND PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES OR BONE DISEASES
CN118121577A (zh) 2018-05-04 2024-06-04 感知神经科学公司 治疗物质滥用的方法
EP4076410A4 (en) * 2019-12-20 2024-02-07 Alar Pharmaceuticals Inc. LONG-ACTING INJECTABLE FORMULATIONS OF KETAMINE PAMOATE SALTS
US20210322669A1 (en) * 2020-04-16 2021-10-21 Invictus Health, Inc. Method for treatment of traumatic brain injuries
CN112263572A (zh) * 2020-11-17 2021-01-26 厦门大学附属翔安医院 右旋氯胺酮在制备治疗脱髓鞘疾病药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048610A1 (en) 2000-01-07 2002-04-25 Cima Michael J. High-throughput formation, identification, and analysis of diverse solid-forms
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
JO2857B1 (en) 2008-06-16 2015-03-15 سانوفي أفينتس Vinyl pipers with modified activity of tumor-resistant TNF
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JP2014196292A (ja) 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
US10793536B2 (en) 2016-03-29 2020-10-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Vortioxetine pamoic acid salt and crystal form thereof
CA3048485C (en) 2016-12-26 2022-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
AU2019206950B2 (en) * 2018-01-10 2021-07-01 XWPharma Ltd. Prodrugs of ketamine, compositions and uses thereof

Also Published As

Publication number Publication date
RS65271B1 (sr) 2024-03-29
DK3908570T3 (da) 2024-02-26
CN113423686A (zh) 2021-09-21
LT3908570T (lt) 2024-03-12
BR112021013340A2 (pt) 2021-09-14
JP7451538B2 (ja) 2024-03-18
SI3908570T1 (sl) 2024-04-30
EP3908570A1 (en) 2021-11-17
ES2974259T3 (es) 2024-06-26
JP2022518003A (ja) 2022-03-11
PE20211550A1 (es) 2021-08-16
TW202042796A (zh) 2020-12-01
WO2020143762A1 (en) 2020-07-16
EP3908570B1 (en) 2023-12-13
SG11202104792SA (en) 2021-06-29
US20220119338A1 (en) 2022-04-21
AU2020206826B2 (en) 2024-05-02
PT3908570T (pt) 2024-03-15
PH12021551157A1 (en) 2021-11-03
CL2021001803A1 (es) 2021-12-24
CA3118954A1 (en) 2020-07-16
TWI827783B (zh) 2024-01-01
US11981617B2 (en) 2024-05-14
KR20210116517A (ko) 2021-09-27
AU2020206826A1 (en) 2021-06-03
FI3908570T3 (fi) 2024-02-13
CO2021006884A2 (es) 2021-06-10
HRP20240255T1 (hr) 2024-05-24
EP3908570A4 (en) 2022-10-19
CN113423686B (zh) 2023-08-22

Similar Documents

Publication Publication Date Title
PH12021551157A1 (en) Ketamine pamoate and use thereof
MX2020009956A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
GEP201706748B (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2009006285A (es) Inhibidores de transcriptasa inversa no nucleosidicos.
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
EP4316591A3 (en) Oxysterols and methods of use thereof
TW200730506A (en) Compounds and uses thereof
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2021004280A (es) Derivados de pirazol como compuestos antagonistas de receptor de histamina h4.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
GEP20237522B (en) Antibacterial compounds
MX2021010700A (es) Compuestos utiles en la terapia del vih.
MX2021003427A (es) Nuevos oxadiazoles.
MX2019010898A (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cancer.
MX2022005111A (es) Compuestos moduladores del receptor 52 acoplado a proteina g (gpr52).
MX2019006768A (es) Peptidos antimicrobianos.
MX2021014794A (es) Acidos 1-fenil-5-azinilpirazolil-3-oxialquilicos y su uso para combatir el crecimiento no deseado de plantas.
BR112023025789A2 (pt) Nitroxolina para uso no tratamento de neurofibroma cutâneo
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders